Learn About Pseudomyxoma Peritonei

What is the definition of Pseudomyxoma Peritonei?
Pseudomyxoma peritonei (PMP) is a rare disease characterized by the presence of mucin in the abdominal (peritoneal) cavity. While the most common cause of PMP is appendix cancer, several types of tumors (including non-cancerous tumors) can cause PMP. Signs and symptoms may include an increase in abdominal size or bloating; inguinal hernia (in men); an ovarian mass that may be felt during a routine pelvic exam (in women); pain or discomfort in the abdomen; and/or appendicitis.
Save information for later
Sign Up
What are the alternative names for Pseudomyxoma Peritonei?
  • Pseudomyxoma peritonei
  • Adenomucinosis
  • Gelatinous ascites
  • PMP
  • Syndrome of pseudomyxoma peritonei
Who are the top Pseudomyxoma Peritonei Local Doctors?
Learn about our expert tiers
Learn more
What are the latest Pseudomyxoma Peritonei Clinical Trials?
Register With Data From Patients With the Diagnosis of a Peritoneal Surface Malignancy, for Which Cytoreductive Surgery and Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) is Performed

Summary: The purpose of this study is to register the follow-up data of patients who, because of a peritoneal surface malignancy, will undergo cytoreductive surgery and HIPEC.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors

Summary: This trial will look at a drug called SGN-STNV to find out whether it is safe for patients with solid tumors. It will study SGN-STNV to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study how well SGN-STNV works to treat solid tumors. The study will have two parts. Part A of the study will find out how much SGN-STNV should be give...

Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center

What are the Latest Advances for Pseudomyxoma Peritonei?
Pleural decortication and hyperthermic intrathoracic chemotherapy for pseudomyxoma.
Efficacy and safety in the use of intraperitoneal hyperthermia chemotherapy and peritoneal cytoreductive surgery for pseudomyxoma peritonei from appendiceal neoplasm: A systematic review.
Tired of the same old research?
Check Latest Advances
Early postoperative intraperitoneal chemotherapy (EPIC) following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in 632 patients with pseudomyxoma peritonei of appendiceal origin: A single institution experience.